Celldex Therapeutics

Celldex Therapeutics

Yahoo Finance • 2 months ago

Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best biotech stocks on this list. TheFly reported on June 10 that UBS increased its price targe... Full story

Yahoo Finance • 2 months ago

Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is one of the best low-priced pharma stocks on this list. TheFly reported on June 11 that XERS announced th... Full story

Yahoo Finance • 2 months ago

Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera

(RTTNews) - This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical readouts spanning therapeutic areas inclu... Full story

Yahoo Finance • 2 months ago

Celldex Presents New Phase 2 CSU Data For Barzolvolimab In Angioedema; BLA Planned For 2027

(RTTNews) - Celldex (CLDX), a biopharmaceutical company, on Sunday reported positive data from the Phase 2b trial showing sustained effects of Barzolvolimab in treating Angioedema in patients with chronic spontaneous urticaria. Results wer... Full story

Yahoo Finance • 2 months ago

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseasesCDX-622 targets the soluble form of stem cell factor (SCF), depleting mast cells witho... Full story

Yahoo Finance • 5 months ago

Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch

* Celldex Therapeutics (CLDX [https://seekingalpha.com/symbol/CLDX]) priced [https://seekingalpha.com/pr/20460246-celldex-announces-pricing-of-300-million-public-offering-of-common-stock] an underwritten public offering of ~10.3M shares... Full story

Yahoo Finance • 5 months ago

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 10,345,000 shares of its common stock at a public... Full story

Yahoo Finance • 5 months ago

Celldex Therapeutics announces public offering of common stock

* Celldex Therapeutics (CLDX [https://seekingalpha.com/symbol/CLDX]) announced on Wednesday that it has commenced an underwritten public offering for the sale of shares of its common stock. * In addition, Celldex expects to grant the u... Full story

Yahoo Finance • 5 months ago

Celldex Announces Proposed Public Offering of Common Stock

HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it has commenced an underwritten public offering for the sale of shares of its common stock. In... Full story

Yahoo Finance • 5 months ago

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding

Kynam Capital Management disclosed in a February 17, 2026, SEC filing that it sold 1,720,949 shares of Cogent Biosciences(NASDAQ:COGT), an estimated $48.38 million trade based on quarterly average pricing. What happened According to a SE... Full story

Yahoo Finance • 5 months ago

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Kynam Capital Management trimmed its stake in Viridian Therapeutics(NASDAQ:VRDN), selling 2,957,386 shares in the fourth quarter, an estimated $81.11 million transaction based on quarterly average pricing, according to a February 17, 2026,... Full story

Yahoo Finance • 5 months ago

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know

Kynam Capital Management reduced its position in CG Oncology(NASDAQ:CGON), selling 1,059,375 shares in the fourth quarter for an estimated $43.84 million based on quarterly average pricing, according to a February 17, 2026, SEC filing. Wh... Full story

Yahoo Finance • 5 months ago

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish

Kynam Capital Management disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals(NASDAQ:SNDX), an estimated $8.18 million trade based on quarterly average pric... Full story

Yahoo Finance • 6 months ago

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

- Late breaking Poster Presentation at AAAAI - - Ability to retreat facilitates a real-world paradigm in which treatment for ColdU and SD may be intermittent with barzolvolimab - HAMPTON, N.J., March 01, 2026 (GLOBE NEWSWIRE) -- Cellde... Full story

Yahoo Finance • 6 months ago

Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory

We came across a bullish thesis on Celldex Therapeutics, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on CLDX. Celldex Therapeutics, Inc.'s share was trading at $30.82 as of February 25th.test, cancer,... Full story

Yahoo Finance • 6 months ago

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

- Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks - - Greatly improved quality of life and reduced disease impa... Full story

Yahoo Finance • 6 months ago

Celldex Therapeutics Stock Earns 88 RS Rating

On Thursday, Celldex Therapeutics stock received an upgrade to its Relative Strength (RS) Rating, from 63 to 88. This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price ac... Full story

Yahoo Finance • 6 months ago

Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSU Topline data expected Q4 2026 BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 2026 (GLOBE... Full story

Yahoo Finance • 7 months ago

Celldex to Present at Upcoming Investor Conferences

HAMPTON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026 o... Full story

Yahoo Finance • 8 months ago

Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best small cap stocks to buy with huge upside potential. Barclays lifted the price target on Celldex Therapeutics, Inc. (NASDAQ:CLDX) to $24 from $21 on December 17 and reaffirmed an E... Full story